Views from the Chair: Olivier Lortholary praises the ‘high scientific level’ of presentations (Time: 33 seconds)
Who should care about fungal infections? Matteo Bassetti explains (Time: 34 seconds)
Faouzi Saliba on the need for an individualised approach to patients (Time: 61 seconds)
Patricia Munoz on bringing the specialities together (Time: 20 seconds)
Andrew Ullmann on the path to treatment guidelines (Time: 49 seconds)
Manuel Cuenca-Estrella on the challenge of implementing guidelines (Time: 41 seconds)
The Institut Pasteur is the natural home for this meeting. Matteo Bassetti explains why (Time: 33 seconds)
Patricia Munoz: ‘all of us learned something’ (Time: 33 seconds)
Matteo Bassetti gives a speaker’s perspective (Time: 45 seconds)
Manuel Cuenca-Estrella: a mixed-speciality faculty makes for a ‘great experience’ (Time: 28 seconds)
Why this symposium is useful for a hospital physician: Georg Langebartels gives his view (Time: 45 seconds)
Guillaume Brunin on the benefits of the symposium for a practising hospital doctor (Time: 66 seconds)
Olivier Lortholary: local epidemiology is key (Time: 41 seconds)
Emmanuel Roilides: Candida in neonates is a ‘major pathogen’ (Time: 30 seconds)
Mahmoud Ghannoum: ‘It’s an exciting time for biofilm research’(Time: 43 seconds)
Manuel Cuenca-Estrella on the quest for new diagnostic techniques(Time: 58 seconds)
An 18-strong faculty, led by Olivier Lortholary, gave their perspectives on invasive candidiasis from a number of specialist viewpoints.
The Institut Pasteur, "birthplace of microbiology" and venue for the meeting
The meeting focused on the recent European Society of Clinical Microbiology and Infectious Diseases (ESCMID) treatment guidelines, and their implementation. The extensive faculty made for a diverse programme – all of which was filmed and is now available for viewing here. Topics ranged from basic clinical definitions (for example, the important differences between empiric, pre-emptive and targeted treatment) right through to the emergence of new and sophisticated diagnostic techniques.
The meeting took place on the hallowed ground of the Institut Pasteur. Prof. Lortholary described the institution as “a unique place in the world for research,” reminding attendees of the 10 Nobel Prizes which have been awarded to researchers at the Paris campus.
The 2-day gathering brought together 504 clinicians from 21 European countries
Agenda highlights included Manuel Cuenca-Estrella on strategies for diagnosis, Paul Verweij on future diagnostics (including biomarkers),Mahmoud Ghannoum and Emilio Bouza on the impact of biofilms, and William Hope on antifungal agents.
Mixed with individual presentations were a number of case studies, highlighting the need for an individualised approach to treatment. Patricia Munoz dealt with patients requiring renal replacement therapy, pointing out that “These patients are special. They have individual needs and differences…it’s not easy to prescribe Fluconazole to a patient on renal replacement therapy. It can be done, but it’s not easy. We need more data on antifungals in these patients.”
Sessions were interactive, with extensive discussion forums and keypad voting for all participants
Vincent Julien discussed patients with HIV, reminding attendees that “Drug-drug interactions between antiretrovirals and antifungal agents can have profound results.” Faouzi Saliba focused on solid organ transplantation patients. The specific needs of haematology patients and neonates were also examined, and further discussions centred on the question of empirical versus pre-emptive treatment, particularly in the ICU and haematology settings.
Emmanuel Roilides addressed the question of diagnosing candidemia in children: “We have problems with non culture-based methods which are not optimised for children. We can’t rely on non-cultural markers when dealing with babies.” Paulo Manzoni went further, highlighting issues with disease management in neonates: “Fungal infections in neonates are associated with poor cognitive and motor functions at 24 months. That’s why there’s a trend towards prophylaxis. The problem is understanding the true burden of candidemia. The true extent is very high.”
Olivier Lortholary, Meeting Chairman: "Treatment of invasive candidiasis in our hospitals today should be based on a more individualised approach."
Several speakers highlighted an emerging theme in the meeting: the need for clinicians to treat every case individually, and to consider local epidemiology. According to Faouzi Saliba, who spoke on chemoprevention of Candida infection in high-risk settings, “Fungal infections occur mostly in severely ill patients, in immuno-compromised patients. Each organ, each host, each setting has its peculiarity…and our strategies for preventing and treating fungal infection need to be adapted to the profile of each patient.”
Central to the programme was Andrew Ullman’s compelling story of how a committee of experts worked on the evolving treatment guidelines. “There were so many guidelines out there,” he explained. “We were dominated by US guidelines, which are not always applicable…ESCMID gave us a travel grant so the committee could meet at weekends to discuss our guidelines. This meant we were truly independent. In developing the guidelines, we kept asking what do physicians want? Which option benefits the patient? Is the chosen option truly better?”
Matteo Bassetti: "The important thing for the microbiologists is time to identification. We can't wait for blood cultures to be available... we can't wait for the identification of species."
Attendees placed a high value on the clinical relevance of the presentations, and on the mixed viewpoints of the expert presenters. According to Guillaume Brunin, an intensivist from France, “The meeting has given me the chance to meet physicians from different countries, and to be able to discuss the differences in our practices. It’s really interesting, to mix up the specialities.” Georg Langebartels, attending from Germany, said: “For me, it’s important to get some answers to some key questions concerning my patients. I think invasive candidiasis is a very great challenge. We have very much to learn, and I think this meeting can be part of the solution.”
Faouzi Saliba: "Our strategies for preventing and treating fungal infections need to be adapted to the profile of each patient."
Prof. Lortholary seemed to enjoy his chairmanship of a fruitful meeting. “The first goal of the meeting was educational…it’s great to have this exchange on a European basis. I think the invited speakers were very open-minded. I appreciated the interaction of the audience.”